Ponatinib (AP24534)

Catalog No.S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Cited by 65 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )
Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )
Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NETTN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvocFRKSzVyPUCuNFAxODByMEO1PUDPxE1?	NWXI[YxoW0GQR1XS
MV-4-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3ZTWM2OD1yLkCwNFA6PTZizszN	MXnTRW5ITVJ?
MEG-01	NYPCXXFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX4TWM2OD1yLkCwNFEzQCEQvF2=	MYHTRW5ITVJ?
LAMA-84	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlW1TWM2OD1yLkCwNFE3PSEQvF2=	NYnieZM6W0GQR1XS
CGTH-W-1	NF;ZSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGwN4NGUUN3ME2wMlAxOTZ7IN88US=>	Ml\HV2FPT0WU
KASUMI-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2CwTWlEPTB;MD6wNFIyPyEQvF2=	NH3wcYFUSU6JRWK=
BE-13	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjPTWM2OD1yLkCwNlU6KM7:TR?=	MXvTRW5ITVJ?
CTV-1	NX;TdotHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj3UGZ7UUN3ME2wMlAxPTJzIN88US=>	M{j5cnNCVkeHUh?=
NKM-1	M4n3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEC2OVUh\|ryP	NGTEfHRUSU6JRWK=
MONO-MAC-6	M2fkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEC4N\|ch\|ryP	NGLwSlBUSU6JRWK=
A204	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm2TWM2OD1yLkCxNlE5KM7:TR?=	NIL5WGxUSU6JRWK=
GDM-1	M2rtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEG4N\|Mh\|ryP	M2Ox[3NCVkeHUh?=
AN3-CA	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDkTWM2OD1yLkCxPFc{KM7:TR?=	NHf0S2tUSU6JRWK=
BL-70	NUHQOVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIezc\|NKSzVyPUCuNFIyQTlizszN	NXO1V3FbW0GQR1XS
Daudi	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fWfGlEPTB;MD6wNlU{PyEQvF2=	M{XyVXNCVkeHUh?=
KU812	NEi3[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLBTWM2OD1yLkCyPFQ5KM7:TR?=	MXfTRW5ITVJ?
KG-1	M2i2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPSTWM2OD1yLkCzNlk1KM7:TR?=	NUjqdnNNW0GQR1XS
DOHH-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMES4NFMh\|ryP	MWLTRW5ITVJ?
HuO9	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEW0OFgh\|ryP	M2ftR3NCVkeHUh?=
EB2	NYWwcoR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LjZWlEPTB;MD6wOVU4PiEQvF2=	NInhR3dUSU6JRWK=
G-402	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT2VIJKSzVyPUCuNFY{PDFizszN	NYrySohjW0GQR1XS
SU-DHL-1	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LoWmlEPTB;MD6wOlM4QSEQvF2=	NYCzRWtmW0GQR1XS
NCI-H719	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\ZTWM2OD1yLkC3PFg5KM7:TR?=	NV3seJV[W0GQR1XS
MLMA	NGTiT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3uTWM2OD1yLkC5NFYh\|ryP	NIfBdo1USU6JRWK=
KM12	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;JUIdKSzVyPUCuNFk4OzdizszN	M2e4bXNCVkeHUh?=
SUP-T1	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfncGlKSzVyPUCuNFk6QDJizszN	NVnBd3F{W0GQR1XS
MZ1-PC	NUnrZ4Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn0OIdKSzVyPUCuNVE{OzZizszN	MmjCV2FPT0WU
MFE-296	NWH5R4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzsTWM2OD1yLkGxPFM6KM7:TR?=	NUG3VFhOW0GQR1XS
ALL-PO	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTiVYRoUUN3ME2wMlEzPDR\|IN88US=>	NVzMbHloW0GQR1XS
GB-1	M3juUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\1UWlEPTB;MD6xNlUyOiEQvF2=	NInoOJZUSU6JRWK=
SIG-M5	NXjROJB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXn[np7UUN3ME2wMlE{OzdizszN	Mn3SV2FPT0WU
P30-OHK	MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37hVmlEPTB;MD6xOVY4OiEQvF2=	NEDteFlUSU6JRWK=
NCI-H716	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPiTWM2OD1yLkG2NlY3KM7:TR?=	NFPK[YxUSU6JRWK=
MPP-89	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\nbpdxUUN3ME2wMlE3QTN\|IN88US=>	MWPTRW5ITVJ?
SF126	M3LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXH1T417UUN3ME2wMlE4ODZ\|IN88US=>	M3\JRnNCVkeHUh?=
CTB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW1TWM2OD1yLkG3N\|E3KM7:TR?=	MYrTRW5ITVJ?
CA46	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn2[HcyUUN3ME2wMlE4PDh7IN88US=>	MmLZV2FPT0WU
NCI-H520	NH;LVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMUe3N\|Ih\|ryP	MkjyV2FPT0WU
CAL-85-1	NV3KUYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonNTWM2OD1yLkG3PVI4KM7:TR?=	NXj0PINkW0GQR1XS
NCI-H2342	NVvMPWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPzTWM2OD1yLkG4OVc4KM7:TR?=	MUHTRW5ITVJ?
697	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PoPWlEPTB;MD6xPFg4OSEQvF2=	MVLTRW5ITVJ?
NY	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHhTWM2OD1yLkG5Nlg4KM7:TR?=	MlzFV2FPT0WU
T98G	M1PUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:1Sm85UUN3ME2wMlE6OzF6IN88US=>	MWTTRW5ITVJ?
NCI-H1703	NGnNUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMUm2NVUh\|ryP	MlvlV2FPT0WU
NCI-H2087	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3roN2lEPTB;MD6yNFQ{QSEQvF2=	MlzZV2FPT0WU
PF-382	M1XObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknlTWM2OD1yLkKwPFc{KM7:TR?=	M{HS[XNCVkeHUh?=
HCT-116	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;lVWlEPTB;MD6yNVA3QSEQvF2=	NYG5OlhZW0GQR1XS
CAKI-1	M{PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHuTWM2OD1yLkKxOlY3KM7:TR?=	NUXFUlQ6W0GQR1XS
CCF-STTG1	M1HXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMkK0O\|Uh\|ryP	MoPQV2FPT0WU
D-392MG	M4HWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLCZ\|RKSzVyPUCuNlMyPzdizszN	NYGwN2RVW0GQR1XS
RT-112	M3PXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjUV29KSzVyPUCuNlM4QTVizszN	MkO1V2FPT0WU
MES-SA	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PYXGlEPTB;MD6yOFE5PyEQvF2=	NWXuRVF[W0GQR1XS
LC-2-ad	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Ho[WlEPTB;MD6yOFI3PSEQvF2=	NFjHSFdUSU6JRWK=
NOS-1	M1nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPVV4JiUUN3ME2wMlI1OzZ5IN88US=>	NVjNdWVuW0GQR1XS
NALM-6	NFXscohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33UWmlEPTB;MD6yOVU1OyEQvF2=	NX;QOmo6W0GQR1XS
TE-15	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnt[Fd1UUN3ME2wMlI3ODlzIN88US=>	M1W4VnNCVkeHUh?=
786-0	NF:y[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMk[yNlgh\|ryP	MkXuV2FPT0WU
IST-MES1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;jW20{UUN3ME2wMlI3QDJ7IN88US=>	NELmdlJUSU6JRWK=
KYSE-180	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPRSnAzUUN3ME2wMlI3QDlzIN88US=>	NYTBOIczW0GQR1XS
YT	NVeyPWhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;lN2NzUUN3ME2wMlI3QTd2IN88US=>	NFXMWWxUSU6JRWK=
A427	NEPvNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PobGlEPTB;MD6yO\|I3PCEQvF2=	NV25TJlSW0GQR1XS
KYSE-450	NIXT[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DnXGlEPTB;MD6yO\|MzQSEQvF2=	MlHaV2FPT0WU
HuH-7	NIT6bG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTTOYJVUUN3ME2wMlI4PzZ\|IN88US=>	M4\PbHNCVkeHUh?=
CAS-1	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMkizNFMh\|ryP	M{DvbXNCVkeHUh?=
KURAMOCHI	NIL4SmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjhN4FwUUN3ME2wMlI5PDF7IN88US=>	MY\TRW5ITVJ?
ACHN	NES4W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTxOGxKSzVyPUCuNlk{OjNizszN	MY\TRW5ITVJ?
HGC-27	NF64WWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjvRWxpUUN3ME2wMlI6OzV\|IN88US=>	NXTMW4plW0GQR1XS
A172	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV25UG9mUUN3ME2wMlI6PTd5IN88US=>	NYO4b5VDW0GQR1XS
SNU-449	NF7pZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\nWWlEPTB;MD6yPVk3PCEQvF2=	NV31NIF1W0GQR1XS
SW982	NV[3ZWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;EO2lEPTB;MD6yPVk4QCEQvF2=	MX;TRW5ITVJ?
EFO-21	NV3COXZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTvTWM2OD1yLkOwOFEyKM7:TR?=	NF\4fYNUSU6JRWK=
NCI-H2030	NHvmTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXCN5BTUUN3ME2wMlMyOTZ2IN88US=>	NHy0eI9USU6JRWK=
HT-144	NH;x[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4OyVmlEPTB;MD6zNVI5KM7:TR?=	M{LxW3NCVkeHUh?=
MFE-280	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFW2TIhKSzVyPUCuN\|E1PTNizszN	NWKxUFlXW0GQR1XS
SK-LU-1	NIXoOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfYNIhWUUN3ME2wMlMyPDZ4IN88US=>	NU\YTFRtW0GQR1XS
NCI-H2052	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPqTWM2OD1yLkOxOFg1KM7:TR?=	NHHCcWdUSU6JRWK=
SK-HEP-1	M1S2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnqTWM2OD1yLkOzN\|Y5KM7:TR?=	MnnxV2FPT0WU
QIMR-WIL	NH7UVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DBe2lEPTB;MD6zN\|QzPCEQvF2=	MYnTRW5ITVJ?
A2780	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTubFNKSzVyPUCuN\|Q{ODRizszN	Mn7KV2FPT0WU
ACN	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwM{S4O\|Mh\|ryP	M4HJOnNCVkeHUh?=
BxPC-3	M4\C[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvVVFF{UUN3ME2wMlM1QTh7IN88US=>	M32xNnNCVkeHUh?=
BCPAP	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHJTWM2OD1yLkO2NFAyKM7:TR?=	NEjKNpBUSU6JRWK=
HOP-62	NFvFc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLPfGF7UUN3ME2wMlM3OTB4IN88US=>	MVTTRW5ITVJ?
SW1710	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwM{[0OVUh\|ryP	NVqzU2l1W0GQR1XS
OPM-2	NFT5fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3zVpFKSzVyPUCuN\|Y1PzNizszN	MkfaV2FPT0WU
DBTRG-05MG	M3nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7JfHh2UUN3ME2wMlM5ODV2IN88US=>	NELMUohUSU6JRWK=
SK-MEL-24	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXHZ5lZUUN3ME2wMlM6PzlzIN88US=>	MlPFV2FPT0WU
8305C	M{\a[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP3UIlvUUN3ME2wMlM6Pzl\|IN88US=>	MU\TRW5ITVJ?
OVCAR-4	NH\hfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwNEG1PFYh\|ryP	M1\xVnNCVkeHUh?=
HLE	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;4TWM2OD1yLkSxPFYh\|ryP	NFzqWYtUSU6JRWK=
NCI-H747	NWfvSWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzKXllKSzVyPUCuOFIyOzdizszN	NXTTO2RHW0GQR1XS
SW780	NG\zc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrFTWM2OD1yLkSyN\|Q3KM7:TR?=	MVPTRW5ITVJ?
KYSE-150	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\CTWM2OD1yLkSyOFE2KM7:TR?=	M4[3bXNCVkeHUh?=
H4	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7nOmpJUUN3ME2wMlQzPDVzIN88US=>	Mm\NV2FPT0WU
SW1088	NXLUOFF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr1TWM2OD1yLkS0N\|kh\|ryP	M4fUUnNCVkeHUh?=
SF268	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTYTWM2OD1yLkS0PFYh\|ryP	MkXHV2FPT0WU
RT4	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfFTWM2OD1yLkS1NVEyKM7:TR?=	NV;WfJhYW0GQR1XS
NCI-H522	M2ryWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HsemlEPTB;MD60OVI4KM7:TR?=	NHS1N49USU6JRWK=
LCLC-97TM1	NG\HfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jCT2lEPTB;MD60OlE6PSEQvF2=	NVnERmxTW0GQR1XS
CAL-39	NW\4d\|dzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDLPVhKSzVyPUCuOFY2OTlizszN	MXPTRW5ITVJ?
CAL-120	M3;VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\UTWM2OD1yLkS3OlQ{KM7:TR?=	NHX3SI5USU6JRWK=
ESS-1	M17ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwNEe4NlEh\|ryP	MoWyV2FPT0WU
KARPAS-45	NYC1bZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzHcItKSzVyPUCuOFg6OzNizszN	NX;YUnZrW0GQR1XS
DU-4475	M2PXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nOTWlEPTB;MD60PVUyOSEQvF2=	NWDvdWxiW0GQR1XS
VMRC-RCZ	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD1yLkS5PVA1KM7:TR?=	Ml7vV2FPT0WU
HOS	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwNUCzOlUh\|ryP	NVX3T293W0GQR1XS
MOLT-16	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwNUG4NFgh\|ryP	MVzTRW5ITVJ?
RPMI-6666	NFvLe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{THPGlEPTB;MD61NlE{PSEQvF2=	MknLV2FPT0WU
K052	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXvTW9KSzVyPUCuOVIyPCEQvF2=	NWj2WWlYW0GQR1XS
EHEB	NHHNd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjxN285UUN3ME2wMlUzOTh{IN88US=>	NIHpVlVUSU6JRWK=
MFH-ino	NXS4dodHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XzTmlEPTB;MD61NlM2OSEQvF2=	NFL4WnpUSU6JRWK=
A4-Fuk	M{TEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkH5TWM2OD1yLkWyOVI5KM7:TR?=	NYm3R5ZsW0GQR1XS
SW1417	M3n3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrkcpNKSzVyPUCuOVI4QDFizszN	MWfTRW5ITVJ?
DoTc2-4510	M1PS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;mVoxzUUN3ME2wMlU1QTV6IN88US=>	Mne2V2FPT0WU
TE-12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M161cGlEPTB;MD61OVc{PSEQvF2=	MlTlV2FPT0WU
8-MG-BA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPmTWM2OD1yLkW2NFU3KM7:TR?=	NIj4UWZUSU6JRWK=
ECC12	NW\v[mVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj2TWNKSzVyPUCuOVY2PThizszN	MWjTRW5ITVJ?
CHL-1	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwNUe0OlMh\|ryP	NEDidmRUSU6JRWK=
LCLC-103H	M4ewOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDjOIhKSzVyPUCuOVg{PDRizszN	M3XIOXNCVkeHUh?=
OS-RC-2	NV;HSYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLPTWM2OD1yLkW4N\|c6KM7:TR?=	NET0boVUSU6JRWK=
RO82-W-1	M3O3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwNUm2NVUh\|ryP	MWfTRW5ITVJ?
A3-KAW	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH0PVdKSzVyPUCuOlE1PjdizszN	MlrPV2FPT0WU
NCCIT	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;oTWM2OD1yLk[xO\|E2KM7:TR?=	M{m2O3NCVkeHUh?=
IST-SL2	M1;IWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLaTWM2OD1yLk[yOVIzKM7:TR?=	M13Fd3NCVkeHUh?=
GI-ME-N	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwNkOwOlkh\|ryP	MofiV2FPT0WU
ES6	NIrh[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjNXmtKSzVyPUCuOlMzQTVizszN	MmnrV2FPT0WU
BL-41	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPDTWM2OD1yLk[zN\|UzKM7:TR?=	NF;YNphUSU6JRWK=
Ca-Ski	M1nOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HOPWlEPTB;MD62OFgyKM7:TR?=	NFLpcpJUSU6JRWK=
HOP-92	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXmTHJYUUN3ME2wMlY2Pjd{IN88US=>	NVXtbmNrW0GQR1XS
SK-LMS-1	M1TWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzpTWM2OD1yLk[2OFch\|ryP	NGjYVo1USU6JRWK=
EW-13	NEOyZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNk[3O\|kh\|ryP	NGi4S\|lUSU6JRWK=
647-V	NHfXPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfUTWM2OD1yLk[4NVQ5KM7:TR?=	M1jUcXNCVkeHUh?=
JiyoyeP-2003	M37E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn4VYhNUUN3ME2wMlY6PzN6IN88US=>	MljkV2FPT0WU
WSU-NHL	NYn5fWRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwN{C4PFch\|ryP	M2KzenNCVkeHUh?=
U-698-M	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHLUlRKSzVyPUCuO\|ExPjNizszN	M3zBRnNCVkeHUh?=
HC-1	NWLTRZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPqTWM2OD1yLkeyOFA2KM7:TR?=	NHjrWYNUSU6JRWK=
8505C	NV;EfVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwN{K3OFEh\|ryP	NH3RNGhUSU6JRWK=
HUTU-80	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HpSGlEPTB;MD63N\|M1QSEQvF2=	NFToUohUSU6JRWK=
LB1047-RCC	NG[2TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX30[FJNUUN3ME2wMlc{PTN6IN88US=>	MXvTRW5ITVJ?
GAMG	NI\vO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nLTmlEPTB;MD63N\|Y2OyEQvF2=	NYTKeYRxW0GQR1XS
CAL-12T	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PpWWlEPTB;MD63N\|g4PyEQvF2=	NH\6NZBUSU6JRWK=
NCI-SNU-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jQemlEPTB;MD63O\|I4QCEQvF2=	NFL0bVJUSU6JRWK=
HTC-C3	NXrUdmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfWWG4yUUN3ME2wMlc4PDVzIN88US=>	NWTEeJlJW0GQR1XS
HPAF-II	M1TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwN{e1NFEh\|ryP	NWH4[2hQW0GQR1XS
KGN	M{\WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fOcmlEPTB;MD63PFA5OSEQvF2=	NGq4OoxUSU6JRWK=
EFO-27	NYjWNXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfkUoxGUUN3ME2wMlc5PzN\|IN88US=>	M3rWNXNCVkeHUh?=
MEL-HO	M3frS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHJTWM2OD1yLke5OFQ6KM7:TR?=	NVTzTI57W0GQR1XS
KYSE-270	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[2PGlEPTB;MD64NFUzQSEQvF2=	M{T0R3NCVkeHUh?=
NCI-H1755	NGnmNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrBfVZKSzVyPUCuPFA4OTRizszN	M4jReXNCVkeHUh?=
MFM-223	NEj5S\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwOEG0NFch\|ryP	NEXlbWtUSU6JRWK=
G-361	NF3Fb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv4bXZzUUN3ME2wMlgyQDl5IN88US=>	Ml;jV2FPT0WU
ETK-1	M3y2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwOEK0OFEh\|ryP	NFfocIFUSU6JRWK=
LU-99A	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwOES3NFEh\|ryP	M4fTbnNCVkeHUh?=
IST-MEL1	NU\ZXlk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwOEW3N\|Ih\|ryP	NVrRb4JYW0GQR1XS
L-540	M4nXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITXenVKSzVyPUCuPFU5ODFizszN	NF\ye2dUSU6JRWK=
U-2-OS	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XmfmlEPTB;MD64OVg1PiEQvF2=	MYrTRW5ITVJ?
HT-1376	NIPITHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwOE[wOVEh\|ryP	Mkm5V2FPT0WU
COLO-680N	NV\JfFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;wUlY2UUN3ME2wMlg4QTN\|IN88US=>	NInEW3dUSU6JRWK=
NCI-H1581	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XqW2lEPTB;MD64PVI6PyEQvF2=	NV7YOGc1W0GQR1XS
HuCCT1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwOEm1OFgh\|ryP	M3jKVnNCVkeHUh?=
BB30-HNC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[4TIZZUUN3ME2wMlkzPDZ7IN88US=>	M{XmUXNCVkeHUh?=
NCI-H2347	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;zTWM2OD1yLkmzNlkzKM7:TR?=	MnW0V2FPT0WU
G-401	NVnSOmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7W[2dNUUN3ME2wMlk{Pjl3IN88US=>	MWTTRW5ITVJ?
NCI-H358	M4\kWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7ydJRWUUN3ME2wMlk2ODF2IN88US=>	MXvTRW5ITVJ?
HCC1395	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7BVlZHUUN3ME2wMlk2PDZzIN88US=>	MmPZV2FPT0WU
J82	NWCx[YNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTRTWM2OD1yLkm1OVQ{KM7:TR?=	MVHTRW5ITVJ?
KE-37	M13kSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTLXYJQUUN3ME2wMlk3Ozh5IN88US=>	NYfhcpdsW0GQR1XS
NOMO-1	NVq5SnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPUWFBKSzVyPUCuPVY2PjRizszN	MkHpV2FPT0WU
ML-2	NHL0N\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwOUm3OUDPxE1?	MXPTRW5ITVJ?
SW872	NV3XWZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwOUm3O\|Uh\|ryP	M1e3fHNCVkeHUh?=
KYSE-520	M4L6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULQ[ZVVUUN3ME2xMlAxPDl2IN88US=>	NHj5PZBUSU6JRWK=
HL-60	NXLkXJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFwMEC5O{DPxE1?	M1;uZXNCVkeHUh?=
HDLM-2	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rjTGlEPTB;MT6wNVI2OiEQvF2=	M{XUSnNCVkeHUh?=
MIA-PaCa-2	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ETWM2OD1zLkCxN\|c2KM7:TR?=	M1z0eXNCVkeHUh?=
TCCSUP	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjPfFVvUUN3ME2xMlAyPzN{IN88US=>	M{Gwc3NCVkeHUh?=
SH-4	M2G3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwMEKyOFQh\|ryP	NGjhWZpUSU6JRWK=
MG-63	Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXDTWM2OD1zLkCyOlE3KM7:TR?=	M1;3TXNCVkeHUh?=
NB6	NWDkRndCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP1W\|hKSzVyPUGuNFMyODlizszN	NXK0bIh4W0GQR1XS
CAL-54	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoixTWM2OD1zLkCzPVU6KM7:TR?=	NWXBRlQ6W0GQR1XS
DU-145	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLwbHZKSzVyPUGuNFgxPzNizszN	M2XGNHNCVkeHUh?=
HCE-4	M1n3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPUTWM2OD1zLkC5Nlg3KM7:TR?=	MlrwV2FPT0WU
U-266	NEe4S5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwMEm2N\|Mh\|ryP	NYPYOllbW0GQR1XS
HT-1197	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GyNmlEPTB;MT6xNVQ{QCEQvF2=	NXTTT5VIW0GQR1XS
EW-1	NFnae5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLaOHdKSzVyPUGuNVQyOjhizszN	NVjxV5RPW0GQR1XS
MHH-NB-11	M3\WPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfNeXB6UUN3ME2xMlE2OzZ6IN88US=>	MlXWV2FPT0WU
NCI-H2405	M3rPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTiTWM2OD1zLkG2NVYh\|ryP	NIHXUHVUSU6JRWK=
COLO-668	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrITWM2OD1zLkG2OFkh\|ryP	NHO2U2VUSU6JRWK=
IMR-5	NX;mTWszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFwMU[5N\|Yh\|ryP	NIfjS\|lUSU6JRWK=
ARH-77	NUfVNJZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDkeJZzUUN3ME2xMlIzQTJ2IN88US=>	MXPTRW5ITVJ?
BHT-101	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXuUGpZUUN3ME2xMlI{PDlizszN	MnrjV2FPT0WU
SCC-25	NE[4fmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLKO4JRUUN3ME2xMlI{PTN4IN88US=>	NFfNV4xUSU6JRWK=
NTERA-S-cl-D1	M4\aZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOz[lhKSzVyPUGuNlQ{PDZizszN	NXXYb4twW0GQR1XS
MKN28	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjydphSUUN3ME2xMlI2PjN4IN88US=>	NF;TPIRUSU6JRWK=
KS-1	NEjzV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXZTWM2OD1zLkK4NlY6KM7:TR?=	MXfTRW5ITVJ?
NCI-H1734	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnYfWhKSzVyPUGuNlg6OTNizszN	NWHhXXdZW0GQR1XS
ES7	M{Ky[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO3TWM2OD1zLkK5OVQzKM7:TR?=	M2\6UHNCVkeHUh?=
NCI-H838	M3fpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvIN3loUUN3ME2xMlMxPjF3IN88US=>	M2q5ZnNCVkeHUh?=
HEC-1	NX\uVoVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HvZmlEPTB;MT6zN\|c2PSEQvF2=	M3m2R3NCVkeHUh?=
ME-180	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnW[YZKSzVyPUGuN\|c6QTNizszN	M1v2fXNCVkeHUh?=
MMAC-SF	NIDTTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDnXYNKSzVyPUGuN\|k2QTVizszN	NIXkUotUSU6JRWK=
IA-LM	NUThem9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\PTWM2OD1zLkSwPVE1KM7:TR?=	NHXOSIlUSU6JRWK=
MN-60	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr0Vm5KSzVyPUGuOFMyOTRizszN	M12zfXNCVkeHUh?=
SIMA	NUTUNohbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEX2T2hKSzVyPUGuOFg3QDdizszN	NIG1RZZUSU6JRWK=
NCI-H1770	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFwNUKwOVQh\|ryP	Mm[1V2FPT0WU
ONS-76	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTFwNUKzNVEh\|ryP	M{TQZ3NCVkeHUh?=
LB771-HNC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[1eXBKSzVyPUGuOVM6ODZizszN	MoPZV2FPT0WU
SW48	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XLRmlEPTB;MT61OFI1OyEQvF2=	NYHnN2ozW0GQR1XS
KYSE-140	NFPsVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwNUW3OFEh\|ryP	MXTTRW5ITVJ?
SW626	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\FOWxKSzVyPUGuOVgyPiEQvF2=	M3nYNnNCVkeHUh?=
MC-CAR	M37KVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLvOmJKSzVyPUGuOVg3PjNizszN	Mlm1V2FPT0WU
D-336MG	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS4RplKSzVyPUGuOlI6PCEQvF2=	MlH4V2FPT0WU
SK-MEL-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHYTI5lUUN3ME2xMlY{QTB{IN88US=>	M3XSNnNCVkeHUh?=
MHH-PREB-1	M{HYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTFwNkS0O\|Mh\|ryP	MVLTRW5ITVJ?
Calu-1	M4rrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;2TWM2OD1zLk[1N\|g3KM7:TR?=	M3fObnNCVkeHUh?=
HCC1806	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj4TWM2OD1zLk[2OlEyKM7:TR?=	MmjBV2FPT0WU
A101D	NHfze3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHJNmhKSzVyPUGuOlY4QDFizszN	NVflPJhpW0GQR1XS
A704	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHDTWM2OD1zLk[4N\|EyKM7:TR?=	MW\TRW5ITVJ?
LB831-BLC	Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFwNkm4OVQh\|ryP	NUn0TFlFW0GQR1XS
RL95-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwN{G0OlMh\|ryP	M2nNNnNCVkeHUh?=
RPMI-2650	NYXuZ4NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq5TWM2OD1zLkeyO\|E6KM7:TR?=	MnzUV2FPT0WU
NH-12	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDtTWM2OD1zLkezOFI4KM7:TR?=	MnLjV2FPT0WU
AGS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLZZ3J4UUN3ME2xMlc3OzV6IN88US=>	NF\n[\|RUSU6JRWK=
NEC8	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjHWVlrUUN3ME2xMlc5QTl3IN88US=>	MoG2V2FPT0WU
NCI-H2009	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLDRYpKSzVyPUGuO\|k4OjFizszN	NULWXVRkW0GQR1XS
A498	M2HMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYqzUo9FUUN3ME2xMlgyOjh{IN88US=>	MmLMV2FPT0WU
NCI-H810	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G4d2lEPTB;MT64NVYxPiEQvF2=	NHnDd4FUSU6JRWK=
SK-NEP-1	NHLheJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXjTmlKSzVyPUGuPFM4PjdizszN	MmrJV2FPT0WU
D-542MG	M2HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTFwOEW4OVEh\|ryP	NFLjXVJUSU6JRWK=
KNS-42	M4HFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[3dGlEPTB;MT64OlI3PiEQvF2=	NWDn[3VRW0GQR1XS
NCI-H2452	NV;DfmlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYe3O3NGUUN3ME2xMlg6ODd2IN88US=>	MXfTRW5ITVJ?
SK-MEL-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTFwOUCyO\|Eh\|ryP	M3fNcHNCVkeHUh?=
OVCAR-5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfJUllKSzVyPUGuPVA3PzVizszN	MWHTRW5ITVJ?
SNG-M	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTUTWM2OD1zLkm1PFU5KM7:TR?=	M1nFbXNCVkeHUh?=
A673	NFrNRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwOUe1NVYh\|ryP	Mlj1V2FPT0WU
L-428	NUS2PYczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjUdpFKSzVyPUGuPVkyPzlizszN	MULTRW5ITVJ?
KM-H2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTJwMEGwPUDPxE1?	NVj6U\|NCW0GQR1XS
MC-IXC	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJwMEKyO\|Mh\|ryP	NHfrb2ZUSU6JRWK=
COLO-678	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:1W2lEPTB;Mj6wOFIxPyEQvF2=	MX\TRW5ITVJ?
MEL-JUSO	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HLOmlEPTB;Mj6wO\|g2OSEQvF2=	MYPTRW5ITVJ?
HCC38	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJwMEi0N\|Mh\|ryP	NYW0SVQ5W0GQR1XS
UACC-62	NUTrNIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[0UGlEPTB;Mj6wPFg2PSEQvF2=	MnfsV2FPT0WU
OAW-42	NFTZT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTJwMEm3NVEh\|ryP	NVzWXWc{W0GQR1XS
LB996-RCC	NI\GcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[5Spd3UUN3ME2yMlE{QDF5IN88US=>	M4jnWnNCVkeHUh?=
COR-L105	NVXCeJg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn6UFZ7UUN3ME2yMlE3Ozd\|IN88US=>	MXzTRW5ITVJ?
RCC10RGB	NXXXSXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnWTWM2OD1{LkG4OVc3KM7:TR?=	NEjxbZVUSU6JRWK=
A431	M4Owcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTCSW1sUUN3ME2yMlE6ODF7IN88US=>	NVrBbIZFW0GQR1XS
NCI-H292	NHTCO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTJwMkO5OVEh\|ryP	NEfkTJZUSU6JRWK=
SK-UT-1	NEPwVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7YXXRWUUN3ME2yMlM{OTh2IN88US=>	MljNV2FPT0WU
PANC-08-13	M{Pld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rodWlEPTB;Mj6zN\|I{PSEQvF2=	M3LSUXNCVkeHUh?=
ST486	M4Tybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTGTWM2OD1{LkSxNFQ5KM7:TR?=	NVHOW5U2W0GQR1XS
SJSA-1	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvNVIVyUUN3ME2yMlQyOjdzIN88US=>	MmrzV2FPT0WU
RKO	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zFXWlEPTB;Mj60NlAzQSEQvF2=	NX:4dXJIW0GQR1XS
NCI-H1793	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj3TWM2OD1{LkS0NFI6KM7:TR?=	M{jZfHNCVkeHUh?=
639-V	NGHBVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPWUlNKSzVyPUKuOFU{QDJizszN	M1\ZW3NCVkeHUh?=
ES3	NX;DdGpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rUN2lEPTB;Mj60PVc{PyEQvF2=	NXPmS5h5W0GQR1XS
NCI-H1792	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3l[5liUUN3ME2yMlU3QDJ4IN88US=>	MX\TRW5ITVJ?
NCI-H1651	M1HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLaTWM2OD1{LkW4NlEh\|ryP	NV63bm5jW0GQR1XS
SN12C	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJwNUi0PFch\|ryP	NU[z[5JwW0GQR1XS
COLO-679	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzVTWM2OD1{LkW4OlA2KM7:TR?=	NFnzZpZUSU6JRWK=
U-118-MG	M4LT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnMXpFuUUN3ME2yMlU5QDd{IN88US=>	NXLvfYFMW0GQR1XS
Ramos-2G6-4C10	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGe5NIhKSzVyPUKuOlQ5ODdizszN	Mlj4V2FPT0WU
HCT-15	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTJwNki3PVIh\|ryP	MlnwV2FPT0WU
MDA-MB-157	NYrNdI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLLW\|RuUUN3ME2yMlcxPzR5IN88US=>	NULsVmk1W0GQR1XS
K5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXCTWM2OD1{LkexPFQ2KM7:TR?=	NEjv[mVUSU6JRWK=
MKN45	NH7UfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknuTWM2OD1{LkezN\|Y3KM7:TR?=	NWLKVIFWW0GQR1XS
DMS-273	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJwN{W2N\|Ih\|ryP	NUPqc2IxW0GQR1XS
C8166	M2PQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYna[GRIUUN3ME2yMlc5PTF\|IN88US=>	M2TldHNCVkeHUh?=
Calu-3	M32w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrpTWM2OD1{Lke4PVY6KM7:TR?=	MX;TRW5ITVJ?
SNB75	NVTybZplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;ZNlRKSzVyPUKuPFg2OzVizszN	MojRV2FPT0WU
BFTC-905	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGydYpKSzVyPUKuPVAyQTFizszN	NWnWfIJjW0GQR1XS
C-4-II	NVq1cJdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXuybXRyUUN3ME2yMlkyOzV\|IN88US=>	MkfpV2FPT0WU
MS-1	NGP6d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLXXWlKSzVyPUKuPVY4PjlizszN	NGG5VWxUSU6JRWK=
A375	NVf2U3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PDfGlEPTB;Mz6wPFE5PCEQvF2=	NV:yS\|ZXW0GQR1XS
KYSE-70	NV7BTpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTNwMEi4PFIh\|ryP	NUjpUmRSW0GQR1XS
KYSE-510	NX3E[nVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTNwMUC5PVUh\|ryP	MmHxV2FPT0WU
LN-405	NVywblFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nSdmlEPTB;Mz6xN\|UyQCEQvF2=	NYW1TJpjW0GQR1XS
BOKU	M3qwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPNTWM2OD1\|LkG0NlU3KM7:TR?=	NIXJOJFUSU6JRWK=
TE-10	NV;UdppsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL3co9QUUN3ME2zMlE4OzZ{IN88US=>	MV;TRW5ITVJ?
MKN1	M{TGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnixTWM2OD1\|LkG4OFg{KM7:TR?=	MmLJV2FPT0WU
M059J	NHzJXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LIdmlEPTB;Mz6yNFE4OyEQvF2=	M2TPSnNCVkeHUh?=
GOTO	NWLy[VJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnCTWM2OD1\|LkKyNFM6KM7:TR?=	M3rU[XNCVkeHUh?=
DK-MG	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\SR\|JYUUN3ME2zMlI2QTd4IN88US=>	MlS3V2FPT0WU
NCI-H727	NUDzdWZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvxcndKSzVyPUOuNlY2QCEQvF2=	NF7vNGVUSU6JRWK=
NB12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnHZnFYUUN3ME2zMlM{OjJ2IN88US=>	NF\OOnJUSU6JRWK=
DOK	NHvZSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzPVJMzUUN3ME2zMlM3OTh4IN88US=>	M1LXeHNCVkeHUh?=
KYSE-410	NUTNV4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTNwM{[yPFch\|ryP	NILYVGtUSU6JRWK=
AM-38	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LXWGlEPTB;Mz6zPFA2OSEQvF2=	NH7vN3VUSU6JRWK=
GR-ST	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTNwNEW3N\|Ih\|ryP	MWTTRW5ITVJ?
D-247MG	M2rZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\oTGJKSzVyPUOuOFgzPjNizszN	MWPTRW5ITVJ?
TE-8	NULyOJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\VTWM2OD1\|LkS5N\|M{KM7:TR?=	MXrTRW5ITVJ?
LS-411N	NGjQS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n0UWlEPTB;Mz60PVY6OiEQvF2=	Ml3pV2FPT0WU
SK-MES-1	M4PUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTNwNU[0N\|Mh\|ryP	M3npUnNCVkeHUh?=
SF295	NGi0TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLXTWM2OD1\|Lk[xOVUzKM7:TR?=	MYnTRW5ITVJ?
SK-MEL-30	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTNwNkW5NlEh\|ryP	NEfiU5dUSU6JRWK=
LB2241-RCC	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;1c3NKSzVyPUOuOlYzPiEQvF2=	MYnTRW5ITVJ?
PC-14	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLRTWM2OD1\|Lk[2OFM4KM7:TR?=	Moj0V2FPT0WU
EW-7	M3rOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvUUVRIUUN3ME2zMlY4Pjl\|IN88US=>	NY\SRXlTW0GQR1XS
NMC-G1	NXLGcY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLITWM2OD1\|LkexPFM4KM7:TR?=	MmTJV2FPT0WU
TE-441-T	NGHaS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PZVGlEPTB;Mz63N\|AzQCEQvF2=	NUjVUnhnW0GQR1XS
NCI-H1618	M{H2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[0TWM2OD1\|LkixPFc2KM7:TR?=	NY\iNYo2W0GQR1XS
PANC-03-27	NEO4cWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\JT2lEPTB;Mz64NVkyPiEQvF2=	M3Xn[XNCVkeHUh?=
NCI-H2228	M3PXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofETWM2OD1\|LkizNVI3KM7:TR?=	MkO4V2FPT0WU
CAPAN-1	M3TyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P6eGlEPTB;Mz64O\|AxQSEQvF2=	MV7TRW5ITVJ?
KLE	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjqfpVFUUN3ME2zMlkxPjdizszN	M3z4bHNCVkeHUh?=
Becker	M1HLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTNwOUK4OFkh\|ryP	MlfNV2FPT0WU
SK-PN-DW	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3XVWRVUUN3ME20MlA4QTd2IN88US=>	NXTONYNEW0GQR1XS
Hs-578-T	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXeyRllCUUN3ME20MlA5OzB4IN88US=>	MVzTRW5ITVJ?
RS4-11	M{DIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHnTWM2OD12LkGxNlU2KM7:TR?=	MWTTRW5ITVJ?
D-502MG	NXnrN\|R5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPESo81UUN3ME20MlE3QTl5IN88US=>	MoTCV2FPT0WU
GI-1	M2jTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37aSGlEPTB;ND6yPFI6QSEQvF2=	MXvTRW5ITVJ?
NCI-H209	NFLkeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLpTWM2OD12LkOzO\|gh\|ryP	M1\XNnNCVkeHUh?=
SK-OV-3	NHXGNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTSXVI1UUN3ME20MlQ5OTR7IN88US=>	NE\WNGVUSU6JRWK=
LOUCY	M1znPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnewTWM2OD12LkS4OFMzKM7:TR?=	NF2yZnlUSU6JRWK=
NCI-H69	NIe0SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fJdmlEPTB;ND61NVc6OyEQvF2=	M1y4OnNCVkeHUh?=
SCC-9	NHPzXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTXV3VKSzVyPUSuOVMyPzJizszN	MYjTRW5ITVJ?
NCI-H526	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnQTWM2OD12LkW5Nlk{KM7:TR?=	Mnr3V2FPT0WU
NCI-H2170	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfVTWM2OD12Lk[2O\|cyKM7:TR?=	M1TnbHNCVkeHUh?=
SR	NUHiSoo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTRwN{CwOFgh\|ryP	MnXMV2FPT0WU
CMK	NYnuWHRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH64b2FKSzVyPUSuO\|IyODFizszN	MXLTRW5ITVJ?
COLO-829	NFLNSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7jTWM2OD12Lke3NFQ{KM7:TR?=	Ml\0V2FPT0WU
HuO-3N1	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTRwOEOyPFEh\|ryP	Mnq0V2FPT0WU
5637	NYTzfFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnuOFdKSzVyPUSuPVA1QDdizszN	Mom4V2FPT0WU
A253	NGrjb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vE[mlEPTB;ND65O\|cxQCEQvF2=	MXHTRW5ITVJ?
NB10	NV3mfJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmP6TWM2OD13LkC3OFk4KM7:TR?=	NYn3NnFDW0GQR1XS
SF539	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHtTWM2OD13LkC5PVU6KM7:TR?=	NVLZfY43W0GQR1XS
HAL-01	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTVwMUS2OFUh\|ryP	MlzUV2FPT0WU
MHH-ES-1	NUHQWFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvBZoZKSzVyPUWuNVY6OjVizszN	MoHEV2FPT0WU
DEL	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLYOpZKSzVyPUWuNlc2QDJizszN	NHXKeXRUSU6JRWK=
NCI-H1299	NWO5NFZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS2UZRKSzVyPUWuN\|UxODdizszN	MX7TRW5ITVJ?
ChaGo-K-1	NGPte\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTVwM{WxNFch\|ryP	NH:zfGxUSU6JRWK=
HMV-II	M2GxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnve3dKSzVyPUWuN\|k1OyEQvF2=	M1zrO3NCVkeHUh?=
NB69	NUTNTIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki5TWM2OD13LkO5OlMyKM7:TR?=	M2jSVHNCVkeHUh?=
NCI-H1882	M3TyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;TSZFKSzVyPUWuOFM{PjRizszN	NFjlb3VUSU6JRWK=
SNU-475	NIrUSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\qSWlEPTB;NT60O\|E4OSEQvF2=	NUHDU2pzW0GQR1XS
RXF393	M17xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT4TWM2OD13LkS4OFk1KM7:TR?=	MmPLV2FPT0WU
CAL-51	M37tWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT5RYVWUUN3ME21MlYzQDV\|IN88US=>	NETuPFdUSU6JRWK=
SW1573	NVrmNJdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTVwNkO1N\|Qh\|ryP	M1PrTHNCVkeHUh?=
GCT	NHXJTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fsNmlEPTB;NT63OVkzQSEQvF2=	MXHTRW5ITVJ?
COR-L88	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jqXGlEPTB;NT63Olg1PiEQvF2=	MmHFV2FPT0WU
MDA-MB-134-VI	NUXhXVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfzXJU2UUN3ME21Mlg4PTN4IN88US=>	MlfnV2FPT0WU
NB5	NUXRblJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\EV4ZKSzVyPUWuPVI1PCEQvF2=	NILTOnVUSU6JRWK=
GMS-10	NF7JVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnDe5pXUUN3ME21Mlk3QDZzIN88US=>	NEfpWHBUSU6JRWK=
CHP-212	NH22UFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPjfIlKSzVyPU[uOFgzPjdizszN	MYrTRW5ITVJ?
TE-11	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O0[2lEPTB;Nj61OVE5OiEQvF2=	Ml;GV2FPT0WU
SW962	NXX1R2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LQ[WlEPTB;Nj62OVc4PCEQvF2=	MlfoV2FPT0WU
MZ2-MEL	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;yVXlKSzVyPU[uPFIxOTFizszN	MnLZV2FPT0WU
C-33-A	M{HITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvqSlhQUUN3ME22MlkyPjh6IN88US=>	NYXlfmNDW0GQR1XS
IGR-1	NYSyW\|dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4SyTmlEPTB;Nj65O\|gzPiEQvF2=	NXvBdXdWW0GQR1XS
MOLT-4	M1zjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTdwMUW0NFYh\|ryP	M4Kxe3NCVkeHUh?=
NCI-H1650	M4rLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nsUGlEPTB;Nz6yO\|A1PiEQvF2=	MoLGV2FPT0WU
AsPC-1	NGn4T4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTdwMki2NFUh\|ryP	MYnTRW5ITVJ?
SNU-C2B	NG\FU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTLeGhKSzVyPUeuNlk2PzFizszN	MVHTRW5ITVJ?
MKN7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTdwM{eyN\|Uh\|ryP	NUjwOVhrW0GQR1XS
SW620	M{TST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoSxTWM2OD15LkO4NlA2KM7:TR?=	NXLWbWtrW0GQR1XS
SK-MEL-28	NGTlbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zJTGlEPTB;Nz60NFc6QCEQvF2=	MkPRV2FPT0WU
TE-6	M1rIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnxTWM2OD15LkS0PVA5KM7:TR?=	M2XWe3NCVkeHUh?=
D-263MG	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHvbnRKSzVyPUeuOFU4PjJizszN	MlrUV2FPT0WU
NCI-H1355	M37hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\1TGlEPTB;Nz63O\|AzQSEQvF2=	NYW5cFROW0GQR1XS
DSH1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\ITWM2OD15Lke5O\|YzKM7:TR?=	NXTqc4hDW0GQR1XS
NCI-H460	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHm1[\|NKSzVyPUiuNFA3QTRizszN	NHXqT5hUSU6JRWK=
NCI-H1563	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzoblNKSzVyPUiuNFc2ODhizszN	NEHER5FUSU6JRWK=
SW948	NIC3N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV22eVR1UUN3ME24MlExPzR2IN88US=>	NVHacI9nW0GQR1XS
LK-2	NVP1OFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRThwMUK4N\|Mh\|ryP	MWfTRW5ITVJ?
HT-1080	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnhNllKSzVyPUiuNVMyPzVizszN	NED3WVFUSU6JRWK=
NCI-H441	NFjGVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjrTWM2OD16LkG5N{DPxE1?	NY[xeo8{W0GQR1XS
HSC-4	Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPGTWM2OD16LkK4O\|Ih\|ryP	NFjJ[3JUSU6JRWK=
LXF-289	NYXUcIduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvTTWM2OD16LkO1PVQ{KM7:TR?=	MXTTRW5ITVJ?
MRK-nu-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlK4TWM2OD16LkO2N\|A1KM7:TR?=	NULQOHpoW0GQR1XS
no-11	NGPjS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjrTWM2OD16LkS3NVM{KM7:TR?=	NWPpRZdqW0GQR1XS
SNU-387	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLLVnJKSzVyPUiuOlMzPDZizszN	MnfNV2FPT0WU
Detroit562	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG3SZRKSzVyPUiuO\|U1PTVizszN	M1XpVnNCVkeHUh?=
SW954	M3P6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHRTWM2OD16Lke2PFMzKM7:TR?=	NHK3NGpUSU6JRWK=
P12-ICHIKAWA	NHzv[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRThwN{i5OEDPxE1?	MmTPV2FPT0WU
TE-9	M4rFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRThwOEGwOlIh\|ryP	NHnrVmlUSU6JRWK=
NB13	M4qyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XzR2lEPTB;OD64N\|c6PiEQvF2=	MUjTRW5ITVJ?
BPH-1	M2KySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRThwOEWwPFEh\|ryP	NFjJem1USU6JRWK=
KMOE-2	NG\OcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq5WGNwUUN3ME24Mlg4QDl{IN88US=>	NYnqWINrW0GQR1XS
RPMI-8402	NH3MT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P5OmlEPTB;OD64PVkzPiEQvF2=	MmXVV2FPT0WU
OVCAR-3	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLGXIpUUUN3ME24Mlk4PzN{IN88US=>	NXLiNZR7W0GQR1XS
NCI-H2196	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF2yeGlKSzVyPUiuPVg3ODZizszN	MWjTRW5ITVJ?
MZ7-mel	M17iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXOwTYhWUUN3ME25MlA{PDZizszN	MWfTRW5ITVJ?
GP5d	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;tTo1rUUN3ME25MlA3OzF\|IN88US=>	MUnTRW5ITVJ?
NCI-N87	M2HQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DDUWlEPTB;OT60OFc{OSEQvF2=	MVHTRW5ITVJ?
EW-16	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTlwNES4OFgh\|ryP	MoezV2FPT0WU
Calu-6	NYDrc2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTlwNEm3NFMh\|ryP	M1;PeXNCVkeHUh?=
LC4-1	M2m1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVq3dFdCUUN3ME25MlYzPTdizszN	NWHpPYdkW0GQR1XS
CCRF-CEM	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLSTWM2OD17Lk[4O\|Y3KM7:TR?=	M{XvUXNCVkeHUh?=
BC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2n5R2lEPTB;OT63PFk6KM7:TR?=	MljKV2FPT0WU
NCI-SNU-16	NYH1TVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLFcVZKSzVyPUmuO\|k1QTVizszN	NGTQc41USU6JRWK=
NCI-H28	M{\lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rod2lEPTB;OT64OFk{OyEQvF2=	MWfTRW5ITVJ?
SBC-1	M1\ueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nmRmlEPTB;MUCuNFczKM7:TR?=	MVfTRW5ITVJ?
TUR	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoOwTWM2OD1zMD6xOlU4KM7:TR?=	NFmxXZBUSU6JRWK=
MDA-MB-231	NUG1PZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFyLkKxNVQh\|ryP	M{e5TnNCVkeHUh?=
C3A	NGr5N\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLqTWM2OD1zMD6zNVc6KM7:TR?=	NVzPbVFWW0GQR1XS
SW1990	NXvm[WFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\Eb45QUUN3ME2xNE4{OjhizszN	MoW3V2FPT0WU
NCI-H1993	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP2emVKSzVyPUGwMlU3QTNizszN	MX\TRW5ITVJ?
SK-CO-1	NF;ubnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS4VW9KSzVyPUGwMlc4PyEQvF2=	NUfaNpFxW0GQR1XS
OAW-28	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvsc2xJUUN3ME2xNE46QDh6IN88US=>	NWHQcmp3W0GQR1XS
HN	NUHNcmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2W4SmlEPTB;MUGuNVE{OSEQvF2=	MYTTRW5ITVJ?
NCI-H1304	NFT6boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jubGlEPTB;MUGuNVU4PiEQvF2=	NGq3[m5USU6JRWK=
Daoy	NWjCZpAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULKOI5NUUN3ME2xNU41OzN4IN88US=>	MVLTRW5ITVJ?
VA-ES-BJ	NFvP[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTFzLkexPVUh\|ryP	Mlu3V2FPT0WU
MCF7	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi2OXJLUUN3ME2xNU45OTJ4IN88US=>	NYjkVXd7W0GQR1XS
VM-CUB-1	M2DQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFzLkmwPVEh\|ryP	MnfKV2FPT0WU
IPC-298	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHGTWM2OD1zMT65N\|g{KM7:TR?=	NEDjSo1USU6JRWK=
NCI-H2126	M2PlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HKWmlEPTB;MUKuNFIyQCEQvF2=	NYXmTHBrW0GQR1XS
OVCAR-8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnywTWM2OD1zMj6xNVQyKM7:TR?=	MUPTRW5ITVJ?
SJRH30	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmL5TWM2OD1zMj6yNlk6KM7:TR?=	MUPTRW5ITVJ?
DMS-53	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;RZ2NKSzVyPUGyMlI3PDlizszN	MUPTRW5ITVJ?
NCI-H322M	NGTqc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jIO2lEPTB;MUKuN\|M2PyEQvF2=	MknPV2FPT0WU
RVH-421	NVeycZYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r6VGlEPTB;MUKuOFkxPCEQvF2=	M2fvWHNCVkeHUh?=
Raji	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnSSXBKSzVyPUGyMlYyPCEQvF2=	MmrFV2FPT0WU
MDA-MB-415	NIn6cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7yTWM2OD1zMj62OFQ1KM7:TR?=	NEfFXGRUSU6JRWK=
EFE-184	NFzo[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;PeGlEPTB;MUKuO\|ExPiEQvF2=	NVvNXZhKW0GQR1XS
BFTC-909	NXrq[oJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjTOpIyUUN3ME2xNk46OjR5IN88US=>	MXfTRW5ITVJ?
BHY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn70TWM2OD1zMz6zN\|kh\|ryP	Mn75V2FPT0WU
YKG-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLRTWM2OD1zMz6zO\|Q6KM7:TR?=	M1PGWnNCVkeHUh?=
EW-3	NVjBO25[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrzTWM2OD1zMz63NVY{KM7:TR?=	Ml3iV2FPT0WU
HCC1143	M33UWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoT1TWM2OD1zMz63OFM4KM7:TR?=	Mn\tV2FPT0WU
REH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF\|Lki5PFIh\|ryP	NFfPcotUSU6JRWK=
CESS	NHHMXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTF\|Lkm0PFkh\|ryP	NFuwSpBUSU6JRWK=
EFM-19	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmntTWM2OD1zND6xNVEzKM7:TR?=	NV\yeJdlW0GQR1XS
U031	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn72TWM2OD1zND60NFg2KM7:TR?=	NVS4TGQxW0GQR1XS
ES1	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\ETYlKSzVyPUG0MlQ5PTFizszN	NX3DPWh3W0GQR1XS
HSC-3	M3zkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTF2Lk[yNVUh\|ryP	MUHTRW5ITVJ?
LOXIMVI	M33rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT3WHg6UUN3ME2xOE44ODZ6IN88US=>	MVrTRW5ITVJ?
A388	NHjrTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HiOGlEPTB;MUSuO\|U2PiEQvF2=	NXT4UpZrW0GQR1XS
KP-N-YS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXiTWM2OD1zND63O\|Mh\|ryP	NXy4UWN2W0GQR1XS
Capan-2	NFLzZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n3OmlEPTB;MUSuO\|g3KM7:TR?=	MX7TRW5ITVJ?
SKG-IIIa	NXS2bXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnNXVdRUUN3ME2xOE45QDZ{IN88US=>	M{nkVnNCVkeHUh?=
HEL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELVUXRKSzVyPUG0Mlg6QTdizszN	NH\vPG5USU6JRWK=
BEN	M3LTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPBcYVsUUN3ME2xOE46PzZ4IN88US=>	MYTTRW5ITVJ?
MC116	NVjqNmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH3TWM2OD1zNT6xOVk6KM7:TR?=	MmPVV2FPT0WU
IGROV-1	M{XJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfJWphQUUN3ME2xOU4zOzF5IN88US=>	NHPxZoxUSU6JRWK=
NCI-H1648	NWC1OlZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXwTWM2OD1zNT61N\|A2KM7:TR?=	M1TVT3NCVkeHUh?=
ABC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF3LkiwN\|Mh\|ryP	Ml3RV2FPT0WU
EW-18	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFj0R25KSzVyPUG1Mlk6PzlizszN	NX\xbohyW0GQR1XS
BC-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTF4LkC1OlIh\|ryP	NYT2[3RQW0GQR1XS
NCI-H1437	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF4LkC2Olch\|ryP	MoPNV2FPT0WU
SCC-15	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fJfWlEPTB;MU[uNlgzPSEQvF2=	MoHmV2FPT0WU
TT	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTF4LkW4PFgh\|ryP	Mm\zV2FPT0WU
KINGS-1	NUDpeGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXOwNIRNUUN3ME2xOk45Ojd\|IN88US=>	NVuzSW1mW0GQR1XS
C32	NVK4[5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTF4Lkm3NVch\|ryP	NFjETnRUSU6JRWK=
SBC-5	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF5LkG0O\|kh\|ryP	M{PFOXNCVkeHUh?=
NB1	NFL0XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEe5UY1KSzVyPUG3MlMyQDhizszN	Mmr3V2FPT0WU
EB-3	NFPHV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TkdWlEPTB;MUeuOVc3KM7:TR?=	NGXzfW5USU6JRWK=
NCI-H748	NIrjPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGX5W\|hKSzVyPUG3MlcxOzVizszN	NUXwdXY4W0GQR1XS
IST-SL1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlz3TWM2OD1zNz63OVI3KM7:TR?=	NYrS[4lzW0GQR1XS
WM-115	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13tcmlEPTB;MUeuPFA5PSEQvF2=	NInmNo1USU6JRWK=
NCI-H226	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofkTWM2OD1zNz65OVQ3KM7:TR?=	NHL3OFFUSU6JRWK=
CAL-33	NIrjOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPES5ZCUUN3ME2xPE4zPzhzIN88US=>	NYrQeINCW0GQR1XS
SCC-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTF6LkOyNlkh\|ryP	NYLFV2RJW0GQR1XS
RMG-I	NI\YXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LsOmlEPTB;MUiuOlk1PyEQvF2=	MXTTRW5ITVJ?
KOSC-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTZS3hKSzVyPUG4Mlc4PDZizszN	MY\TRW5ITVJ?
A2058	NHjwW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{WzZWlEPTB;MUiuPFI2PSEQvF2=	NEi1XXJUSU6JRWK=
HCC70	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLzTWM2OD1zOT6zPFk1KM7:TR?=	M4PaUnNCVkeHUh?=
C2BBe1	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF7LkSxOFgh\|ryP	NIrWfIpUSU6JRWK=
NCI-H650	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTF7LkW4PVkh\|ryP	MUfTRW5ITVJ?
CAL-72	NUO2SlN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnUTnhKSzVyPUG5MlY4OzdizszN	M4rUd3NCVkeHUh?=
L-363	NF6yWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv1TWM2OD1{MD6wNlEzKM7:TR?=	NGLBPFVUSU6JRWK=
SNU-423	M1riVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJyLkGwOFMh\|ryP	Ml:xV2FPT0WU
PLC-PRF-5	NYnaVnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fOS2lEPTB;MkCuN\|kxPiEQvF2=	M{LnWnNCVkeHUh?=
SW1463	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrZVIFxUUN3ME2yNE41PTJ3IN88US=>	MWnTRW5ITVJ?
769-P	M1f6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrLTWM2OD1{MD62O\|Y6KM7:TR?=	M2DuSXNCVkeHUh?=
DMS-79	NH7vOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX2TWM2OD1{MD64OFkh\|ryP	M3z2bnNCVkeHUh?=
Saos-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJyLkm1OVYh\|ryP	NUD4ZZY{W0GQR1XS
CHP-126	NYeyPZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7zTWM2OD1{MT60OFYzKM7:TR?=	NYLFWGppW0GQR1XS
SW837	M1vIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJzLkS5N\|kh\|ryP	MUjTRW5ITVJ?
SHP-77	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXDXWlVUUN3ME2yNU43OTJ{IN88US=>	Ml;TV2FPT0WU
DB	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJzLk[xOFIh\|ryP	MX3TRW5ITVJ?
ES5	NE\wTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTJzLk[4OlQh\|ryP	NYrMeoNPW0GQR1XS
COR-L23	NYH2W4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULFWlBiUUN3ME2yNU45ODVzIN88US=>	M3i3[nNCVkeHUh?=
KU-19-19	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjyTWM2OD1{MT64PVgzKM7:TR?=	M4TCfHNCVkeHUh?=
T84	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\xN2lEPTB;MkGuPVgyQSEQvF2=	NVnJZo5qW0GQR1XS
NCI-H630	NVzocXF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XXXWlEPTB;MkKuOVM3OyEQvF2=	MWTTRW5ITVJ?
LU-165	NFTIXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlO5TWM2OD1{Mj61OVQh\|ryP	NILoT2ZUSU6JRWK=
COLO-792	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf6OllKSzVyPUKyMlcyOTFizszN	MoriV2FPT0WU
CAL-62	NUGyd4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zQOGlEPTB;MkKuO\|UyPyEQvF2=	NVTmNYM6W0GQR1XS
HCE-T	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\1emlEPTB;MkKuPFYxPiEQvF2=	NHLtPFBUSU6JRWK=
BB65-RCC	M1LXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ\|LkCzOFQh\|ryP	M4j2SnNCVkeHUh?=
SiHa	M17ISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjrW3BlUUN3ME2yN{4{QTZ6IN88US=>	NVr0NHZHW0GQR1XS
NCI-H2081	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXaTWM2OD1{ND6wOlQyKM7:TR?=	MmTFV2FPT0WU
U251	NGWyR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjhTWM2OD1{ND6wOlY5KM7:TR?=	M1LnWXNCVkeHUh?=
LoVo	NX\ZUIU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPUXI9JUUN3ME2yOE46Ojh{IN88US=>	MXvTRW5ITVJ?
GCIY	NXT6TYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvNOpVKSzVyPUK1MlI5PzdizszN	MY\TRW5ITVJ?
NUGC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJ3LkOzNVYh\|ryP	MYrTRW5ITVJ?
LNCaP-Clone-FGC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\TW2FqUUN3ME2yOU4{PDl6IN88US=>	NGD1e4lUSU6JRWK=
PA-1	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7YTWM2OD1{NT62PFM{KM7:TR?=	MX;TRW5ITVJ?
OE33	M4X5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7GOnR{UUN3ME2yOU43QDV\|IN88US=>	MmrKV2FPT0WU
HT-29	NYjIb5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInZeZhKSzVyPUK1Mlc5PzlizszN	Mo\2V2FPT0WU
RCM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7jTWM2OD1{NT65OlU3KM7:TR?=	NIjxXpJUSU6JRWK=
NCI-H1522	M2iwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknCTWM2OD1{NT65PVEyKM7:TR?=	M1yyNnNCVkeHUh?=
LB373-MEL-D	NIPOT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLW[\|lHUUN3ME2yOk4yPzB6IN88US=>	MoC3V2FPT0WU
NCI-H1436	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLiUY5KSzVyPUK2MlI4OzhizszN	MYnTRW5ITVJ?
COLO-824	NUfSNW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPaT\|R4UUN3ME2yOk41ODB{IN88US=>	MoTlV2FPT0WU
CP50-MEL-B	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJ4LkW2O\|Uh\|ryP	Mnm4V2FPT0WU
EGI-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2e1ZmlEPTB;MkeuNlY6QCEQvF2=	NWTqe3RrW0GQR1XS
LAN-6	NUHieFNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJ5LkO1PVgh\|ryP	MWLTRW5ITVJ?
GAK	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTJ5LkSyNlUh\|ryP	NVrOS3hXW0GQR1XS
MDA-MB-175-VII	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfJOWZKSzVyPUK3MlUxPTNizszN	NEDQR\|NUSU6JRWK=
JVM-2	M{P1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTJ5Lk[2NlIh\|ryP	M2XOOHNCVkeHUh?=
UACC-257	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nGdmlEPTB;MkeuOlg4QCEQvF2=	NVyzepU6W0GQR1XS
SW1783	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJ5Lke3PFMh\|ryP	NELNOGNUSU6JRWK=
HT-3	M1PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVqzVGsxUUN3ME2yPE4zOTZ4IN88US=>	MVzTRW5ITVJ?
RL	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXjPWlKSzVyPUK4MlU6OTFizszN	NUWxNFNlW0GQR1XS
TK10	NXPwboRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXEfo9wUUN3ME2yPE43PTN3IN88US=>	NV;kSmczW0GQR1XS
HT55	NYq1TmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrjbG9KSzVyPUK5MlA2PjVizszN	NEm2WmxUSU6JRWK=
BT-20	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUezcWd4UUN3ME2yPU4xPTh4IN88US=>	M4j1bXNCVkeHUh?=
TGBC24TKB	NHX5VVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XoOWlEPTB;MkmuNVg{OSEQvF2=	MW\TRW5ITVJ?
HSC-2	M2HKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvj[2JKSzVyPUK5MlMxODFizszN	MUnTRW5ITVJ?
COLO-205	NUnwUHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDROoxWUUN3ME2yPU4{QTR2IN88US=>	NXjrO25SW0GQR1XS
GT3TKB	NGTUSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7vTWM2OD1{OT62PFc4KM7:TR?=	NIfRdmpUSU6JRWK=
T47D	NH3NT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1y3XGlEPTB;MkmuPFU5OiEQvF2=	MVTTRW5ITVJ?
OMC-1	NHW0ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PxeWlEPTB;M{CuNVkyQSEQvF2=	NIXMdGpUSU6JRWK=
PFSK-1	NXf6[GM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfSfIFKSzVyPUOxMlI3PTlizszN	NHvSZ5pUSU6JRWK=
JEG-3	NITCVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnO[WdKSzVyPUOxMlM2PjFizszN	NVexZWpHW0GQR1XS
RD	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O0UmlEPTB;M{GuOVEyPSEQvF2=	Ml3GV2FPT0WU
NCI-H64	NHL5TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\WNnBKSzVyPUOyMlQyPzlizszN	NFHVPIpUSU6JRWK=
DMS-114	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH2zZYFKSzVyPUOyMlQyQDJizszN	MlHkV2FPT0WU
NCI-H661	NIS1VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTN{Lk[1NFEh\|ryP	Ml7DV2FPT0WU
CAL-148	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljDTWM2OD1\|Mj62OlY2KM7:TR?=	NGPjN\|RUSU6JRWK=
HuP-T3	M2KxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojITWM2OD1\|Mj65N\|M5KM7:TR?=	MXLTRW5ITVJ?
ES4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mom2TWM2OD1\|Mz6xO\|A2KM7:TR?=	NHrhXFRUSU6JRWK=
Ca9-22	NXTIe3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vCWWlEPTB;M{OuOFYxOSEQvF2=	MVLTRW5ITVJ?
LP-1	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTN2LkC5JO69VQ>?	MkjrV2FPT0WU
AU565	NWHBWo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS0NpZpUUN3ME2zOE42ODZ7IN88US=>	M1HpRnNCVkeHUh?=
MDA-MB-453	M1H5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnh[nRKSzVyPUO1MlE1OjZizszN	MoHpV2FPT0WU
SNU-C1	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTN3LkG3NUDPxE1?	MX;TRW5ITVJ?
SW13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\OZ2lEPTB;M{WuOFA4PiEQvF2=	MWfTRW5ITVJ?
NCI-H2122	NVqwNmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LtTmlEPTB;M{WuOVU6QCEQvF2=	M4TOPXNCVkeHUh?=
NCI-H1395	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HGc2lEPTB;M{WuOlY6OSEQvF2=	MVjTRW5ITVJ?
J-RT3-T3-5	M{X5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTN4LkCyPVQh\|ryP	MULTRW5ITVJ?
COR-L279	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;wTWM2OD1\|Nj6xPVgyKM7:TR?=	NVLBRphSW0GQR1XS
ATN-1	M{TyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe4cJpNUUN3ME2zOk45PTF4IN88US=>	NEn4PJVUSU6JRWK=
HCC2998	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i3c2lEPTB;M{[uPFU4OSEQvF2=	NW\6[4lDW0GQR1XS
UM-UC-3	M{PCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLXTWM2OD1\|Nj64Olc2KM7:TR?=	NFnBVZRUSU6JRWK=
DV-90	M3z5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\QNZVKSzVyPUO2MlkxPjdizszN	M3zDenNCVkeHUh?=
ES8	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHoTWM2OD1\|Nj65N\|E5KM7:TR?=	NEPlTWZUSU6JRWK=
YAPC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT1bWppUUN3ME2zOk46PjV2IN88US=>	M1LiTHNCVkeHUh?=
HCC1599	NH3IO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXU[2JwUUN3ME2zO{4yPjF6IN88US=>	MWfTRW5ITVJ?
UMC-11	NV31TXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDaTWM2OD1\|Nz6yOVA{KM7:TR?=	M{HlVnNCVkeHUh?=
THP-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTvNZBJUUN3ME2zO{4zQDZ6IN88US=>	NVnJTFVMW0GQR1XS
OCUB-M	NXvxWIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnryTWM2OD1\|Nz6yPFkyKM7:TR?=	NX;Cc4dEW0GQR1XS
NCI-H1693	NXjHfot{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O0cGlEPTB;M{euN\|I{OyEQvF2=	MUnTRW5ITVJ?
NCI-H345	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\YTWM2OD1\|Nz6zOlI1KM7:TR?=	MVXTRW5ITVJ?
COLO-800	M{jjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13xVWlEPTB;M{euOVY4KM7:TR?=	M1KzZ3NCVkeHUh?=
COLO-320-HSR	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrpR\|dCUUN3ME2zPE4{PDl{IN88US=>	MWPTRW5ITVJ?
NCI-H596	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTN6LkS0PFkh\|ryP	MmH5V2FPT0WU
NCI-H187	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjlUHQ{UUN3ME2zPE44OzR2IN88US=>	NWHkWVZ7W0GQR1XS
ECC4	MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XGXGlEPTB;M{muNFgyPCEQvF2=	NF3JfoRUSU6JRWK=
KP-4	NGDRNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTN7LkGyN\|Uh\|ryP	M2fZ[XNCVkeHUh?=
NCI-H2227	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3xd5hKSzVyPUO5MlM6PDlizszN	NYLDWnRpW0GQR1XS
22RV1	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITyfmZKSzVyPUO5Mlg{QThizszN	MWDTRW5ITVJ?
SAS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Hxc2lEPTB;NECuNFk3KM7:TR?=	MU\TRW5ITVJ?
PANC-10-05	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq2cmF7UUN3ME20NE4yQDJ6IN88US=>	MoXIV2FPT0WU
MDA-MB-468	NUC0fnJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fhdWlEPTB;NECuOVM1PiEQvF2=	NXLDR2RqW0GQR1XS
RPMI-7951	NXTa[VVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfXWJAxUUN3ME20NU4zODd3IN88US=>	NGPyOWFUSU6JRWK=
BB49-HNC	M4GwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3JSFZKSzVyPUSxMlIyPzlizszN	MljZV2FPT0WU
23132-87	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUG0dYprUUN3ME20NU4zPzN{IN88US=>	MYLTRW5ITVJ?
HCC1569	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3QTWM2OD12MT6yPFg2KM7:TR?=	NUTPfYlGW0GQR1XS
CP66-MEL	NYnWWXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTR{LkG4PFYh\|ryP	NFLjU\|FUSU6JRWK=
K-562	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTR{LkK4OVQh\|ryP	NWrqV2hIW0GQR1XS
OCI-AML2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjmPWp2UUN3ME20Nk45QTd2IN88US=>	M{jvXnNCVkeHUh?=
SW756	NXfy[WhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTR\|LkCzPFgh\|ryP	NW[1d5JOW0GQR1XS
M14	NFq0e\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTibHlKSzVyPUSzMlMyQDlizszN	NVLXcmQ2W0GQR1XS
NCI-H1623	NIDXSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXUOGtKSzVyPUSzMlQ3PCEQvF2=	MnrlV2FPT0WU
KNS-81-FD	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLaTWM2OD12Mz63OlIh\|ryP	MoT5V2FPT0WU
TGBC1TKB	M2nhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17BR2lEPTB;NEOuPVA6QSEQvF2=	M3fmTHNCVkeHUh?=
RERF-LC-MS	NVK1fJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTR\|LkmyPFEh\|ryP	M2XaeXNCVkeHUh?=
PC-3	NWrTTlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPUb\|h[UUN3ME20OE41OzR5IN88US=>	MkTrV2FPT0WU
HuP-T4	NEHXNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEToUnpKSzVyPUS0MlQ1PzRizszN	M3\l[XNCVkeHUh?=
NCI-H510A	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LrSmlEPTB;NESuO\|A5KM7:TR?=	MY\TRW5ITVJ?
LB2518-MEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrYTWM2OD12ND63PVM4KM7:TR?=	MUnTRW5ITVJ?
TE-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPR[nQ5UUN3ME20OU46PThzIN88US=>	NYe5OphFW0GQR1XS
EW-24	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj1[VRKSzVyPUS2MlE4OjNizszN	M1vDVXNCVkeHUh?=
LB647-SCLC	NWXvfWVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4P5PWlEPTB;NE[uNlE2PSEQvF2=	NULKWGhjW0GQR1XS
NCI-H524	NHfNW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16yXGlEPTB;NE[uO\|E5PSEQvF2=	MXXTRW5ITVJ?
EW-11	NIC2OHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3jNXBKSzVyPUS2Mlk{PzNizszN	MX3TRW5ITVJ?
KALS-1	NHq3e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTCNXJKSzVyPUS3MlIxPjZizszN	NHuzXGVUSU6JRWK=
BT-474	NWm5eJAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\YNm1KSzVyPUS3MlQzOTZizszN	M{[yS3NCVkeHUh?=
SK-N-AS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTR5Lki4PEDPxE1?	NV3MOIhOW0GQR1XS
HCC2157	NXPwc2gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\tTWM2OD12OD6wO\|Yh\|ryP	MojaV2FPT0WU
HCC1954	NYHM[5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK1VWdKSzVyPUS4MlE4ODRizszN	NGXFeFBUSU6JRWK=
FADU	NWX4dVdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;ZV4NKSzVyPUS4MlMxOzFizszN	MUfTRW5ITVJ?
S-117	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TZWmlEPTB;NEiuN\|gyPSEQvF2=	NGTn[XNUSU6JRWK=
LS-1034	NVf3WmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR6LkewOlch\|ryP	NEi2[WlUSU6JRWK=
CAMA-1	NGPxO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:4dmlEPTB;NEmuOVU1OyEQvF2=	M4XJPXNCVkeHUh?=
LU-134-A	NGnWW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3OzXGlEPTB;NEmuPFA5PSEQvF2=	NVTxeFZpW0GQR1XS
NCI-H1838	NGHKUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTR7LkiwPFch\|ryP	MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Formulation: Dissolved in 25 mM citrate buffer, pH 2.75 Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 65 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 65 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)